Amedisys enters contract to acquire Beacon Hospice Amedisys.

Amedisys enters contract to acquire Beacon Hospice Amedisys, Inc. , one of America’s leading home health and hospice companies, today announced it offers signed a definitive agreement to obtain Beacon Hospice, Inc www.nizagara100.com nizagara100.com ., and is regarded as one of the premier hospice businesses in the New England area. Founded in 1993, Beacon has grown to include 23 free-standing locations and one inpatient unit, serving the claims of Massachusetts , Maine , New Hampshire , Rhode Island and Connecticut . Total annualized revenue for Beacon this year 2010 was approximately $80 million. This deal remains subject to customary closing conditions, including regulatory approvals, and can be likely to add $0.05 to $0.07 to Amedisys’ earnings in 2011 excluding one-time transaction related costs.

www.nizagara100.com

Related StoriesMRA therapy does not improve outcome in coronary attack patients without heart failureNew test for heart attack may save NHS millionsNew across-the-board Medicare cuts may place many individuals and providers at riskThere were differences in treatment patterns for patients once admitted: the number of patients receiving catheterization was 42 % among those in the 12 hours or greater ED diversion publicity category vs. 49 % in the no diversion category; and number of individuals getting percutaneous coronary intervention was 24 % in 12 hours or greater exposure category vs. 31 % in the no diversion category. Analysis of data indicated that there have been no statistically significant differences in mortality rates between no diversion position and when the contact with diversion was less than 12 hours.

Other Posts From Category "clinical laboratory":

Related Posts